Valuation : Abivax

Market Cap 8.41B 9.78B 7.92B 7.23B 13.53B 923B 13.56B 93.54B 36.3B 474B 36.71B 35.91B 1,526B P/E 2026 *
-27.5x
P/E 2027 * -32.4x
Enterprise Value 7.31B 8.5B 6.88B 6.28B 11.75B 802B 11.79B 81.28B 31.54B 412B 31.9B 31.21B 1,326B EV / Sales 2026 *
97.6x
EV / Sales 2027 * 89.7x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day+1.69%
1 week+1.74%
Current month+1.74%
1 month-13.01%
3 months+11.33%
6 months+4.58%
Current year-17.57%
1 week 95
Extreme 95
100.8
1 month 95
Extreme 95
114.8
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.9
Extreme 3.9
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Exercice

Chief Executive Officer

17,728 0.0222%
7/11/26 Exercice

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
+1.69%+1.74%+31.81%+471.72% 9.78B
-0.90%-2.60%-1.51%+14.05% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
+0.53%-1.36%+16.87%+46.82% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.46%-1.21%+12.11%+31.25% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -0.54%+0.50%+69.19%+150.32% 28.48B
Weighted average by Cap. -0.68%+0.11%+87.26%+141.44%

Financials

2026 *2027 *
Net sales 74.92M 87.07M 70.49M 64.39M 120M 8.22B 121M 833M 323M 4.22B 327M 320M 13.59B 82.73M 96.15M 77.84M 71.11M 133M 9.08B 133M 920M 357M 4.66B 361M 353M 15B
Net income -265M -308M -249M -228M -426M -29.09B -427M -2.95B -1.14B -14.93B -1.16B -1.13B -48.08B -231M -268M -217M -198M -371M -25.32B -372M -2.57B -995M -12.99B -1.01B -985M -41.85B
Net Debt -1.1B -1.28B -1.04B -948M -1.77B -121B -1.78B -12.26B -4.76B -62.07B -4.81B -4.71B -200B -993M -1.15B -934M -853M -1.6B -109B -1.6B -11.04B -4.28B -55.88B -4.33B -4.24B -180B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-09-07 99.25 +1.69% 20,540
26-09-04 €97.60 -1.56% 61,886
26-09-03 €99.15 +2.59% 118,999
26-09-02 €96.65 -1.83% 106,964
26-09-01 €98.45 +0.92% 167,955
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
97.60EUR
Average target price
138.97EUR
Spread / Average Target
+42.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!